New Research Project CureCN Aims to Cure the Ultra-Rare Crigler-Najjar Syndrome
11 international partners from academia, hospitals, healthcare companies and patient organisations meet for official project kick-off in Amsterdam on April 6-7
Amsterdam, 5 April 2018 – The new European research project CureCN focuses on developing a curative gene therapy for the ultra-rare liver disease Crigler-Najjar syndrome (CN) and to make the treatment available to patients. The project includes a clinical trial to prove the safety and efficacy of the gene therapy for the so far incurable liver disorder. The project is funded under the EU Framework Programme for Research and Innovation Horizon 2020 with a total budget of € 6.25 million.